Intercell
Page Module:Infobox/styles.css has no content.Page Template:Infobox company/styles.css has no content.
| Lua error in package.lua at line 80: module 'Module:InfoboxImage/data' not found. | |
Company type | Aktiengesellschaft |
|---|---|
| WBAG: ICLL OTCQX: INRLY | |
| ISIN | Script error: No such module "WikidataIB". |
| Industry | Script error: No such module "WikidataIB". |
| Predecessor | Script error: No such module "WikidataIB". |
| Incorporated | Script error: No such module "WikidataIB". |
| Founded | Script error: No such module "WikidataIB". |
| Founder | Script error: No such module "WikidataIB". |
| Defunct | Script error: No such module "WikidataIB". |
| Fate | Merged with Vivalis SA |
| Successor | Script error: No such module "WikidataIB". |
| Headquarters | , |
Key people | Thomas Lingelbach (CEO), Michel Gréco (Chairman of the supervisory board) |
| Products | Development of vaccines |
| Revenue | Script error: No such module "WikidataIB". |
| Script error: No such module "WikidataIB". | |
| Script error: No such module "WikidataIB". | |
| Total assets | Script error: No such module "WikidataIB". |
| Total equity | €121.1 million (end 2010)[1] |
Number of employees | Script error: No such module "WikidataIB". |
| Parent | Script error: No such module "WikidataIB". |
| Website | www |
Script error: No such module "Check for conflicting parameters".Script error: No such module "Check for deprecated parameters".
Intercell AG was a biotechnology company based in Vienna which focused on the development of modern prophylactic and therapeutic vaccines against infectious diseases. The company merged with Vivalis to form Valneva SE in 2012.[2] Intercell was formed in 1998 as a spin-off of the Research Institute of Molecular Pathology (IMP) in Vienna.[3] It employs 400 people in Austria, Scotland and the United States.
History
It was founded in 1998 and focused on the research, development, and commercialization of vaccines and other biological products. Intercell AG's products were used to prevent and treat a variety of infectious diseases, including hepatitis B, Japanese encephalitis, and pneumonia. In 2012, Intercell AG merged with Vivalis SE, a French biotech company, to form Valneva.[4]
It has been listed on the Vienna Stock Exchange since February 28, 2005. In 2008, Intercell signaled its intent to acquire Maryland-based Iomai, a developer of needle-free vaccination technology.[5][6]
Intercell cooperates with pharmaceutical companies like Novartis, Merck and Sanofi-Aventis on vaccine production.
The most important projects of Intercell are:
- Vaccine against Japanese encephalitis (approved in Europe, America and Australia)[7][8][9]
- Therapeutic vaccine against hepatitis C (in clinical phase II)[10]
- Antigen identification program and adjuvant technologies.
- Vaccine Enhancement Patch to improve prevention against pandemic influenza (in collaboration with U.S. Department of Health and Human Services, in clinical phase II)
References
Page Template:Reflist/styles.css has no content.
- ^ a b c d e f Page Module:Citation/CS1/styles.css has no content."Annual Report 2010" (PDF). Intercell. Archived from the original (PDF) on 26 June 2011. Retrieved 3 May 2011.
- ^ Page Module:Citation/CS1/styles.css has no content.Carroll, John (17 December 2012). "Troubled Intercell throws in the towel, signs off on merger deal with Vivalis". Fierce Biotech. Retrieved 27 January 2018.
- ^ Page Module:Citation/CS1/styles.css has no content."Research Institute of Molecular Pathology (IMP) - About the IMP > History". Research Institute of Molecular Pathology. Retrieved 2009-07-25. [dead link]
- ^ Page Module:Citation/CS1/styles.css has no content."The Dark Horse of the Vaccine Race May Be This French Biotech". Bloomberg.com. 2021-04-29. Retrieved 2023-01-09.
- ^ Page Module:Citation/CS1/styles.css has no content.Fox, Maggie; Grenon, Andre (2008-05-12). "Austrian vaccine maker Intercell buys Iomai". Reuters. Archived from the original on 2011-06-20. Retrieved 2008-08-15.
- ^ Page Module:Citation/CS1/styles.css has no content.Staff (1 June 2008), "Intercell to Acquire Iomai for $189M", Genetic Engineering & Biotechnology News, News: Inside Industry, vol. 28, no. 11, Mary Ann Liebert, Inc., p. 14, ISSN 1935-472X
- ^ Page Module:Citation/CS1/styles.css has no content."Intercell's Japanese Encephalitis Vaccine FDA approval". Medical News Today. 2009-03-31. Retrieved 2009-03-31. [dead link]
- ^ Page Module:Citation/CS1/styles.css has no content."Intercell's Japanese Encephalitis Vaccine EMEA approval for Europe". Intercell. 2009-04-02. Retrieved 2009-04-02. [dead link]
- ^ Page Module:Citation/CS1/styles.css has no content."Intercell's Japanese Encephalitis Vaccine Australian TGA approval". Intercell. 2009-01-23. Retrieved 2009-01-23. [dead link]
- ^ Page Module:Citation/CS1/styles.css has no content."Intercell Hepatitis C Vaccine Meets Primary Endpoints". FDA News. 2007-08-22. Retrieved 2008-08-15.
External links
Lua error in mw.title.lua at line 404: bad argument #2 to 'title.new' (unrecognized namespace name 'Portal').
